Pharmacology in the Catheterization Laboratory

by Waksman, Ron; Ajani, Andrew

• ISBN13: 9781405157049
• ISBN10: 1405157046
• Edition: 1st
• Format: Hardcover
• Copyright: 2009-12-21
• Publisher: Wiley-Blackwell

Summary

This timely reference summarizes the use, risks, dosages, interactions, and alternatives for all drugs commonly used in the catheterization laboratory. For ease of use, each chapter opens with a summary and includes cases and illustrations.

Author Biography

Ron Waksman MD, FACC, Associate Chief of Cardiology Director of Experimental Angioplasty and New Technologies, Division of Cardiology, Washington Hospital Center Washington, DC, USA. Andrew E. Ajani MBBS, MD,FJFICM, FRACP, FCSANZ, Associate Professor, Interventional Cardiologist, Director of Coronary Care Unit Director of Physician Training, The Royal Melbourne Hospital Melbourne, Australia.

Table of Contents

Contributors	p. viii
Acknowledgements	p. xiii
Foreword	p. xiv
Preface	p. xv
Elective PCI anticoagulation therapy/thrombin inhibitors
Optimal antithrombotic therapy	p. 3
Low molecular weight heparin in the catheterization laboratory	p. 10
Direct thrombin inhibitor: Bivalirudin	p. 16
Fondaparinux in the cardiac catheterization laboratory	p. 23
Antiplatelet therapy
Optimal antiplatelet therapy: Duration of antiplatelet therapy with drug-eluting and bare metal stents	p. 33
Clopidogrel: How much, how soon, and how long	p. 41
Loading strategies of clopidogrel	p. 46
Cangrelor	p. 53
Prasugrel: A novel P2Y12 receptor inhibitor	p. 59
When to use glycoprotein IIb/IIIa inhibitors and which one to use: Abciximab, tirofiban, or eptifibatide?	p. 67
Acute coronary syndrome STEMI/NSTEMI
Antithrombotic therapy for non ST-elevation acute coronary syndromes	p. 81
Non antithrombotic postprocedural pharmacotherapy: The role of statins, beta-blockers, angiotensin-converting enzyme, or aldosterone inhibitors in acute coronary syndromes and elective percutaneous coronary interventions	p. 93
Primary percutaneous coronary intervention for ST elevation myocardial infarction: Summary of optimal anticoagulation, glycoprotein IIb/IIIa platelet inhibitors, and other antiplatelet therapies	p. 104
Rescue percutaneous coronary intervention	p. 112
Facilitated primary percutaneous coronary intervention in acute ST-elevation myocardial infarction	p. 118
Streptokinase, alteplase, reteplase, or tenecteplase	p. 133
Intracoronary vs intravenous glycoprotein IIb/IIIa inhibitor use	p. 140
Upstream vs procedural use of glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes	p. 145
High-dose tirofiban	p. 154
Oral anticoagulation issues in percutaneous coronary intervention	p. 158
Elective PCI miscellaneous
Agents to optimize access of radial artery approach	p. 167
High-risk PCI
Diabetes mellitus	p. 173
Cardiogenic shock	p. 179
High-risk coronary intervention and renal dysfunction	p. 190
Renal-protective agents	p. 195
Radiocontrast-induced nephropathy	p. 203
Ideal contrast agent	p. 210
PCI complications
The no reflow phenomenon: Etiology, prophylaxis, and treatment	p. 219
Arrhythmia management in the cardiac catheterization laboratory	p. 227
Tachyarrhythmias management	p. 229
Bradyarrhythmias management (intravenous atropine, adrenaline, indications for temporary pacing wire)	p. 235
Postprocedural pharmacotherapy
Management of patients on long-term anticoagulation	p. 243
Indication for anticoagulation post-percutaneous coronary intervention	p. 250
Clopidogrel use in patients requiring coronary artery bypass grafting	p. 257
Anticoagulation anomalies
Heparin-induced thrombocytopenia	p. 263
Thrombocytopenia, anemia, and transfusion of blood products in patients undergoing percutaneous coronary interventions	p. 270
Antiplatelet therapy resistance: Definition, diagnosis, and clinical implications	p. 280
Reversal of anticoagulation: Protamine	p. 287
Thrombocytopenia post-percutaneous coronary interventions: Glycoprotein IIb/IIIa-induced	p. 294
Systemic pharmacotherapy for in-stent restenosis
Is oral rapamycin plus bare metal stents a feasible alternative to drug-eluting stents? Lessons learned from Argentina observational and randomized studies (ORAR I, II, and III trials)	p. 305
Systemic pharmacotherapy for in-stent restenosis: Steroids	p. 328
Oral agents to prevent in-stent restenosis (oral sirolimus and glitazones)	p. 337
Novel pharmacotherapy in percutaneous coronary intervention	p. 346
Appendix	p. 354
Index	p. 371
Table of Contents provided by Ingram. All Rights Reserved.